Enanta Pharmaceuticals (NASDAQ:ENTA) CEO Jay Luly Sells 4,743 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay Luly sold 4,743 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the transaction, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $14.60 on Friday. The stock’s fifty day simple moving average is $11.89 and its 200 day simple moving average is $9.04. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $15.34. The firm has a market cap of $421.36 million, a price-to-earnings ratio of -3.81 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.The company had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $15.60 million. On average, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. US Bancorp DE bought a new stake in shares of Enanta Pharmaceuticals during the first quarter worth $36,000. Farther Finance Advisors LLC increased its position in Enanta Pharmaceuticals by 11,558.0% in the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,779 shares during the period. MetLife Investment Management LLC bought a new stake in Enanta Pharmaceuticals during the 1st quarter worth about $72,000. Quarry LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter valued at about $81,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JMP Securities boosted their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 12th. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. Evercore ISI decreased their price target on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Westpark Capital increased their target price on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $20.33.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.